Read this topic

HIV (human immunodeficiency virus) can affect the brain in two very different ways, and confusing them is a common trap for exam candidates and new clinicians alike. The first is a slow, indirect, cumulative cognitive decline called HIV-associated neurocognitive disorder (HAND). The second is a group of specific opportunistic infections (infections that only take hold once the immune system is severely weakened) that strike suddenly and dramatically.

For example, imagine two patients with HIV: one has gradually worsening thinking and slowed movements over months, while the other suddenly develops fever and a specific ring-shaped lesion on a brain scan. That second, dramatic presentation reflects a specific opportunistic infection, not the general cognitive decline of HAND.

HAND and opportunistic CNS infection work through entirely different mechanisms and therefore need entirely different work-ups. HAND cannot be cured with a single course of antimicrobial treatment because there is no discrete pathogen to target; treating it as if it were an infection to be cleared, rather than a chronic process to be suppressed via antiretroviral therapy, is a common error.

HAND reflects indirect brain damage from chronic immune activation, rather than HIV directly infecting and destroying neurons (nerve cells). It produces a fairly characteristic picture: slowed thinking, impaired attention, and apathy (a loss of motivation and emotional responsiveness), developing gradually rather than overnight. Opportunistic infections work completely differently: specific pathogens that the immune system normally controls take hold once the CD4 count (a measure of immune cell count, and the standard marker of HIV-related immune damage) falls below roughly 200, especially below 100.

DSM-5 (the Diagnostic and Statistical Manual of Mental Disorders, fifth edition) frames HAND as a spectrum rather than a single fixed diagnosis: at the milder end, objective impairment on cognitive testing with no effect on daily functioning; further along, that impairment starts to interfere with everyday tasks; at the most severe end, a dementia-level picture with clear functional disability. Four opportunistic infections dominate the CNS picture once CD4 falls low enough. Toxoplasma encephalitis (brain inflammation caused by the parasite Toxoplasma gondii) causes multiple ring-enhancing lesions on brain imaging. Progressive multifocal leukoencephalopathy (a demyelinating brain disease caused by reactivation of the JC virus) causes non-enhancing white matter lesions, with no specific antiviral treatment available. Cryptococcal meningitis (fungal infection of the membranes covering the brain and spinal cord) causes headache and raised pressure inside the skull. Cytomegalovirus (CMV) is a further opportunistic pathogen seen in this same severely immunosuppressed group.

Two of these conditions can look identical on a first scan, which is where treatment response itself becomes a diagnostic clue. Consider a patient whose presumed toxoplasma lesion fails to shrink after two weeks of appropriate antiparasitic treatment: that treatment failure should prompt consideration of primary CNS lymphoma (a cancer of lymphoid tissue within the brain) instead, since this can mimic toxoplasma encephalitis on imaging but does not respond to antiparasitic therapy. Similarly, HIV-associated dementia can be distinguished from a straightforward depressive episode by looking for objective psychomotor slowing and imaging changes, rather than relying on mood symptoms alone.

Suspicion is driven first by the CD4 count: for example, imagine a patient with a CD4 count of 50 who develops a new ring-enhancing brain lesion: that low count specifically raises suspicion of an opportunistic infection such as toxoplasma encephalitis, prompting urgent investigation and empirical treatment rather than a slower diagnostic work-up. From there, diagnosis combines the CD4 count, the specific imaging pattern (ring-enhancing versus non-enhancing white matter lesions), cerebrospinal fluid analysis and cryptococcal antigen testing where cryptococcal meningitis is suspected, and, for HAND, staged cognitive testing against the DSM-5 spectrum described above. Response to a trial of treatment becomes part of the diagnostic pathway too, not just an afterthought once a diagnosis is already secure.

The single most important management step across this entire spectrum, from HAND through to opportunistic infection, is antiretroviral therapy (ART): combination medication that suppresses HIV replication and allows the immune system, including the CD4 count, to recover. WHO (World Health Organization) guidance underpins global antiretroviral treatment strategy, with early, sustained treatment reducing the risk of the CD4 count ever falling low enough for opportunistic infections to take hold in the first place. For an individual opportunistic infection, disease-specific treatment: antiparasitic drugs for toxoplasmosis, antifungal drugs plus therapeutic lumbar puncture (draining fluid to relieve pressure) for cryptococcal meningitis, is combined with, rather than replaced by, optimising antiretroviral therapy, since restoring the patient's own immune function is what ultimately prevents relapse and further opportunistic disease. Because PML has no specific antiviral, its management relies entirely on immune reconstitution through ART.

The high-yield trap is treating "HIV plus a new neurological or cognitive problem" as one undifferentiated category. Always ask two questions first: is this gradual (favouring HAND) or acute (favouring an opportunistic infection), and what is the CD4 count: a low count reshapes the whole differential toward toxoplasmosis, PML, or cryptococcal meningitis.

HIV affects the brain through two distinct routes: gradual HAND from chronic immune activation, and acute opportunistic infections once CD4 falls below roughly 200, distinguished by tempo, CD4 count, and imaging pattern, and both are ultimately controlled by starting or optimising antiretroviral therapy.